Nana Safoaah, MD
Internal Medicine · Jersey City, NJNPI 1538795430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 28.8% of the total.
Across 77 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$466
- Novo Nordisk$371
- GSK$324
- Lilly USA, LLC$184
- Astellas Pharma US Inc$122
- Exact Sciences$47
- plus $100 from 4 others
Across 9 payments — averaging $25,245 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$227K
What the payments were for
- Food & beverage$1,614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $466 |
| Novo Nordisk | 17 | $371 |
| GSK | 14 | $324 |
| Lilly USA, LLC | 10 | $184 |
| Astellas Pharma US Inc | 7 | $122 |
| Exact Sciences | 2 | $47 |
| Dexcom, Inc. | 2 | $35 |
| Pfizer | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- FARXIGA$125
How this compares
$1,614 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $25,719 |
| JardianceEmpagliflozin | 17 | $22,700 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,848 |
| JanuviaSitagliptin Phosphate | 11 | $6,461 |
| Atorvastatin Calcium | 140 | $1,622 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $690 |
| Metformin Hcl | 85 | $559 |
| Rosuvastatin Calcium | 31 | $496 |
| Metoprolol Succinate | 35 | $448 |
| Losartan Potassium | 43 | $431 |
| Amlodipine Besylate | 58 | $374 |
| Gabapentin | 23 | $340 |
| Levothyroxine Sodium | 28 | $293 |
| ClopidogrelClopidogrel Bisulfate | 11 | $236 |
| Fluticasone Propionate | 15 | $234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $25,71926 claims |
| GSKTrelegy Ellipta | $324 | $6,84811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Jersey City
- Amer SyedJersey City$140K
- Yasmine ElamirJersey City$47K
- Saquiba SyedJersey City$35K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.